New! Sign up for our free email newsletter.
Science News
from research organizations

Preventing spread of SARS coronavirus-2 in humans

Infection researchers identify potential drug

Date:
March 5, 2020
Source:
Deutsches Primatenzentrum (DPZ)/German Primate Center
Summary:
Infection biologists have investigated how the novel coronavirus SARS-CoV-2 penetrates cells. They have identified a cellular enzyme that is essential for viral entry into lung cells: the protease TMPRSS2. A clinically proven drug known to be active against TMPRSS2 was found to block SARS-CoV-2 infection and might constitute a novel treatment option.
Share:
FULL STORY

Several coronaviruses circulate worldwide and constantly infect humans, which normally caused only mild respiratory disease. Currently, however, we are witnessing a worldwide spread of a new coronavirus with more than 90,000 confirmed cases and over 3,000 deaths. The new virus has been named SARS coronavirus-2 and has been transmitted from animals to humans. It causes a respiratory disease called COVID-19 that may take a severe course. The SARS coronavirus-2 has been spreading since December 2019 and is closely related to the SARS coronavirus that caused the SARS pandemic in 2002/2003. No vaccines or drugs are currently available to combat these viruses.

Stopping virus spread

A team of scientists led by infection biologists from the German Primate Centre and including researchers from Charité, the University of Veterinary Medicine Hannover Foundation, the BG-Unfallklinik Murnau, the LMU Munich, the Robert Koch Institute and the German Center for Infection Research, wanted to find out how the new coronavirus SARS-CoV-2 enters host cells and how this process can be blocked. The researchers identified a cellular protein that is important for the entry of SARS-CoV-2 into lung cells.

"Our results show that SARS-CoV-2 requires the protease TMPRSS2, which is present in the human body, to enter cells," says Stefan Pöhlmann, head of the Infection Biology Unit at the German Primate Center. "This protease is a potential target for therapeutic intervention."

Promising drug

Since it is known that the drug camostat mesilate inhibits the protease TMPRSS2, the researchers have investigated whether it can also prevent infection with SARS-CoV-2. "We have tested SARS-CoV-2 isolated from a patient and found that camostat mesilate blocks entry of the virus into lung cells," says Markus Hoffmann, the lead author of the study. Camostat mesilate is a drug approved in Japan for use in pancreatic inflammation.

"Our results suggest that camostat mesilate might also protect against COVID-19," says Markus Hoffmann. "This should be investigated in clinical trials."


Story Source:

Materials provided by Deutsches Primatenzentrum (DPZ)/German Primate Center. Note: Content may be edited for style and length.


Journal Reference:

  1. Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S. Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020; DOI: 10.1016/j.cell.2020.02.052

Cite This Page:

Deutsches Primatenzentrum (DPZ)/German Primate Center. "Preventing spread of SARS coronavirus-2 in humans." ScienceDaily. ScienceDaily, 5 March 2020. <www.sciencedaily.com/releases/2020/03/200305132039.htm>.
Deutsches Primatenzentrum (DPZ)/German Primate Center. (2020, March 5). Preventing spread of SARS coronavirus-2 in humans. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2020/03/200305132039.htm
Deutsches Primatenzentrum (DPZ)/German Primate Center. "Preventing spread of SARS coronavirus-2 in humans." ScienceDaily. www.sciencedaily.com/releases/2020/03/200305132039.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES